International Journal of Research Publication and Reviews, Vol 6, Issue 6, pp 4677-4684 June 2025

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

# The Efficacy of Furosemide in the Management of Hypertension: A Comprehensive Review

***Sumit.D.Chankhore, Sachin .D.Chalge, Sanket Kakade, Om Chankhore, Madan Chankhore, Rohan Chankhore , Dr. Shivshankar Mhaske, Prof.Satish G. Lodhe***

M. E. S Satyajeet College Pharmacy Mehkar

Abstract

Hypertension represents a major global health challenge and is associated with increased cardiovascular morbidity and mortality. Diuretics remain a cornerstone in the treatment of hypertension, particularly in volume-expanded and resistant cases. Furosemide, a loop diuretic, is commonly indicated for conditions involving fluid overload but is less frequently prescribed solely for hypertension compared to thiazide diuretics. This review comprehensively analyses the pharmacology, clinical efficacy, safety, and clinical guidelines related to the use of furosemide in hypertension management. Particular attention is given to its role in special populations, such as the elderly and patients with renal impairment. The review highlights current evidence, gaps in research, and future directions for optimizing therapy involving furosemide.

## Introduction

Hypertension, or chronically elevated arterial blood pressure, affects an estimated 1.28 billion adults worldwide and is a leading cause of stroke, myocardial infarction, chronic kidney disease, and premature death. Effective blood pressure control reduces cardiovascular risk, making the choice of antihypertensive agents crucial.Treatment guidelines commonly recommend lifestyle modification alongside pharmacotherapy, with diuretics, calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers forming the backbone of drug regimens. Among diuretics, thiazide-type agents are often preferred for uncomplicated hypertension. Nevertheless, furosemide, a potent loop diuretic, has unique pharmacological characteristics that may offer advantages in specific clinical scenarios, warranting thorough examination. This review aims to detail furosemide’s efficacy in treating hypertension, contextualize its pharmacological profile, synthesize clinical trial data, explore its safety and tolerability, and delineate its place in current clinical practice.

## Pharmacology of Furosemide

## Chemical Structure and Classification

Furosemide (chemical formula $C_{12}H_{11}ClN_2O_5S$) is classified as a loop diuretic. It is structurally distinct from thiazide and potassium-sparing diuretics. Furosemide, chemically known as **4-chloro-2-[(furan-2-yl)methylsulfamoyl]benzoic acid**, has the following chemical structure:

- Molecular Formula: $C_{14}H_{14}ClN_3O_5S$
- Molecular Weight: 330.83 g/mol

### Mechanism of Action

Furosemide is a potent loop diuretic that is widely used in the management of conditions such as hypertension, heart failure, and edema. Its pharmacodynamics involves several key mechanisms that contribute to its diuretic and antihypertensive effects.

### Mechanism of Action

1. **Site of Action**: Furosemide primarily acts on the **ascending limb of the loop of Henle** in the nephron. This segment of the nephron is responsible for the reabsorption of sodium, potassium, and chloride ions.
2. **Inhibition of Ion Transporters**: Furosemide inhibits the **Na-K-2Cl cotransporter (NKCC2)**, which is responsible for the reabsorption of sodium (Na+), potassium (K+), and chloride (Cl-) ions from the tubular fluid back into the bloodstream. By blocking this transporter, furosemide prevents the reabsorption of these ions, leading to increased excretion of sodium, chloride, and water.

3. **Diuretic Effect**: The inhibition of the NKCC2 transporter results in:
- **Increased Urinary Output**: The retention of sodium and chloride in the tubular fluid leads to osmotic diuresis, where water follows the solutes into the urine, resulting in increased urine volume.
- **Decreased Blood Volume**: The increased excretion of water reduces blood volume, which in turn lowers blood pressure.
4. **Electrolyte Imbalance**: Furosemide can lead to the loss of electrolytes, particularly potassium (K+), magnesium (Mg2+), and calcium (Ca2+). This is due to the increased delivery of sodium to the distal nephron, where it is exchanged for potassium and hydrogen ions, leading to hypokalemia (low potassium levels) and potential metabolic alkalosis.
5. **Renal Hemodynamics**: Furosemide can also affect renal blood flow. By reducing blood volume, it may initially decrease renal perfusion. However, in cases of heart failure, furosemide can improve renal function by alleviating congestion and improving cardiac output.

**Pharmacokinetics**

1. **Absorption**: Furosemide is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours after oral administration.
2. **Distribution**: It is highly protein-bound (approximately 95%), primarily to albumin, which affects its distribution and bioavailability.
3. **Metabolism**: Furosemide is minimally metabolized in the liver and is primarily excreted unchanged in the urine.
4. **Half-Life**: The elimination half-life of furosemide is approximately 1-2 hours, but its effects can last longer, especially with higher doses.

**Clinical Implications**

- **Dosing**: Due to its potency and rapid action, furosemide is often used in acute settings, such as hypertensive emergencies or acute heart failure. Dosing may need to be adjusted based on renal function and the presence of electrolyte imbalances.
- **Monitoring**: Patients on furosemide require regular monitoring of renal function and electrolytes to prevent complications such as dehydration, hypokalemia, and renal impairment.
- **Combination Therapy**: Furosemide is often used in combination with other antihypertensive agents to enhance blood pressure control and manage fluid overload.

## Clinical Indications for Furosemide

Furosemide is primarily used for edema associated with congestive heart failure, liver cirrhosis, and renal disease. Its use in hypertension is generally reserved for secondary or resistant hypertension, especially where volume overload or impaired renal function complicate management.
Special populations include:

- Elderly patients with reduced plasma renin activity and volume expansion.
- Patients with chronic kidney disease showing resistance to thiazide diuretics.
- Postpartum women with hypertensive disorders.

## Efficacy in Hypertension Management

### Clinical Trials and Studies

A number of randomized controlled trials have investigated the antihypertensive effects of furosemide. A study by Roush et al. (2013) noted that while furosemide effectively lowers blood pressure, it generally requires higher doses compared to thiazides and may be less effective as monotherapy for uncomplicated hypertension. Elderly patients with low plasma renin activity were found to exhibit significant blood pressure reductions with furosemide administration, highlighting its particular efficacy in volume-expanded states (Atkins et al., 2002).
Furosemide has demonstrated utility in managing hypertension in patients with significant renal impairment, where thiazide diuretics lose efficacy.

## Furosemide in Special Populations

Furosemide is widely used in various patient populations, including those with specific comorbidities and demographic characteristics. Understanding its use in these special populations is crucial for optimizing treatment outcomes and minimizing potential side effects. Below are key considerations for the use of furosemide in special populations:

***1. Elderly Patients***

- **Pharmacokinetics**: Elderly patients often have altered pharmacokinetics due to changes in renal function, body composition, and the presence of multiple comorbidities. Dosing adjustments may be necessary to avoid excessive diuresis and electrolyte imbalances.
- **Risk of Falls**: The diuretic effect can lead to dehydration and orthostatic hypotension, increasing the risk of falls and fractures in elderly patients.
- **Monitoring**: Regular monitoring of renal function and electrolytes is essential to prevent complications such as hypokalemia and dehydration.

***2. Patients with Chronic Kidney Disease (CKD)***

- **Efficacy**: Furosemide is often used in patients with CKD to manage fluid overload and hypertension. It can help improve renal perfusion by reducing volume overload.
- **Dosing Considerations**: In advanced CKD, the response to furosemide may be diminished due to reduced renal function. Higher doses may be required, and careful monitoring of renal function and electrolytes is necessary.
- **Combination Therapy**: Furosemide may be used in combination with other diuretics (e.g., thiazides) to enhance diuretic efficacy in patients with resistant edema.

***3. Heart Failure Patients***

- **Management of Edema**: Furosemide is a cornerstone in the management of heart failure, particularly for alleviating symptoms of fluid overload, such as pulmonary congestion and peripheral edema.
- **Dosing**: The dosing of furosemide may need to be adjusted based on the severity of heart failure and the patient's response. Patients may require higher doses during acute exacerbations.
- **Monitoring**: Close monitoring of renal function, electrolytes, and fluid status is critical to avoid complications and ensure effective management.

***4. Pregnant Women***

- **Use in Pregnancy**: Furosemide is generally avoided during pregnancy unless absolutely necessary, as it can affect placental blood flow and fetal development. If used, it should be at the lowest effective dose and for the shortest duration.
- **Alternatives**: Other antihypertensive agents, such as methyldopa or labetalol, are often preferred for managing hypertension in pregnant women.

***5. Pediatric Patients***

- **Dosing**: Furosemide can be used in pediatric patients for conditions such as congenital heart disease and nephrotic syndrome. Dosing is typically based on body weight and should be carefully calculated.
- **Monitoring**: Pediatric patients require close monitoring for electrolyte imbalances and renal function, as they may be more susceptible to the side effects of diuretics.

***6. Patients with Diabetes***

- **Impact on Glucose Metabolism**: Furosemide may affect glucose metabolism and insulin sensitivity, which is particularly relevant for patients with diabetes. Monitoring blood glucose levels is advisable.
- **Combination Therapy**: Furosemide can be used in conjunction with other antihypertensive agents to manage hypertension in diabetic patients, but careful consideration of potential interactions is necessary.

## Role in Hypertension Management

Furosemide is **not typically a first-line antihypertensive agent** according to most guidelines (e.g., JNC 8, ACC/AHA 2017), which favor thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone). However, furosemide may be effective in:

***1. Resistant Hypertension***

- Patients who do not respond to three or more antihypertensive agents, including a diuretic
- Furosemide can help by overcoming fluid retention that may blunt the efficacy of other antihypertensives

***2. Chronic Kidney Disease (CKD)***

- In patients with GFR <30 mL/min, thiazides lose effectiveness
- Loop diuretics like furosemide maintain efficacy at lower GFRs

***3. Heart Failure and Hypertension***

- In hypertensive patients with concomitant heart failure (particularly with volume overload), furosemide helps manage both conditions

*Comparative Efficacy*

- **Blood Pressure Reduction**: Furosemide has a modest effect on blood pressure compared to thiazide diuretics
- **Duration of Action**: Shorter (6–8 hours); often requires twice-daily dosing
- **Electrolyte Effects**: More likely to cause hypokalemia, hypocalcemia, and hypomagnesemia than thiazides

***Adverse Effects***

- **Electrolyte Imbalance**: Hypokalemia, hypomagnesemia, hyponatremia
- **Volume Depletion**: Orthostatic hypotension, dizziness
- **Ototoxicity**: Especially at high doses or with rapid IV administration
- **Hyperuricemia**: Risk of gout

***Clinical Guidelines Perspective***

Most major hypertension guidelines recommend loop diuretics like furosemide only in certain populations:

- **JNC 8**: Prefer thiazides unless contraindicated
- **KDIGO (for CKD)**: Use loop diuretics when eGFR <30 mL/min
- **ESC/ESH 2018**: Reserve for volume overload or low GFR states

## Comparison With Other Antihypertensives

When compared with thiazide diuretics, furosemide's blood pressure lowering effect is comparable if adequate doses are used, although thiazides remain preferred due to longer duration and better tolerability. Meta-analyses suggest diuretics overall reduce cardiovascular morbidity and mortality, with loop diuretics like furosemide offering advantages in specific subgroups but lacking in first-line recommendation for general hypertension.

## Dosage Regimens

Typical oral dosages range from 20mg to 80mg daily, often divided doses for sustained diuresis. Higher doses may be required in kidney dysfunction. Clinical titration must balance efficacy with side effect risk.

## Safety and Side Effects

### Common Side Effects

- Electrolyte disturbances: hypokalemia, hyponatremia, hypocalcemia, hypomagnesemia
- Dehydration and volume depletion
- Hypotension and orthostatic symptoms
- Ototoxicity (rare, mostly with rapid IV administration)

## Long-term Considerations

Chronic furosemide use requires regular monitoring of electrolytes and kidney function. Increased risk of gout and metabolic alkalosis has been documented. Careful dose adjustments are needed to minimize adverse effects.

## 6. Furosemide in Special Populations

### Elderly Patients

Studies demonstrate enhanced blood pressure reduction in elderly hypertensives with low-renin hypertension treated with loop diuretics. Risks of electrolyte imbalance are higher, requiring monitoring.

### Patients with Comorbid Conditions

In heart failure patients, furosemide improves hypertension management while reducing fluid overload. In patients with diabetes, electrolyte imbalance and volume shifts necessitate caution.

## Diuretic and Antihypertensive Actions of Furosemide

This study investigated the diuretic and antihypertensive effects of furosemide in patients with chronic congestive heart failure. It was found that furosemide caused a prompt increase in sodium, potassium, and chloride excretions. Doses of 50, 100, and 200 mg orally produced progressively increasing diuretic responses. When administered over a period of one week to patients with essential hypertension, furosemide in doses of 100 to 200 mg orally per day caused a significant decrease in systolic and diastolic pressure. Biochemical alterations during furosemide administration included elevation of fasting blood sugar levels in patients with diabetes mellitus, increased uric acid concentrations, and lowering of plasma potassium levels. All biochemical changes were reversible when the drug was discontinued.

## Treatment of Benign Essential Hypertension: Comparison of Furosemide and Hydrochlorothiazide

In this study, furosemide (12.5, 25, or 40 mg twice daily) was compared as an antihypertensive with hydrochlorothiazide (12.5 mg twice daily) and a placebo. A double-blind, cross-over design was used with a run-in period of 4 weeks, preceding five 4-week periods of treatment with these compounds alone. The study found that furosemide 25 or 40 mg twice daily and hydrochlorothiazide 12.5 mg twice daily had a similar hypotensive effect, irrespective of the initial blood pressure.

There was a distinct correlation between blood pressure and age. Serum potassium levels fell significantly during treatment, particularly with hydrochlorothiazide 12.5 mg twice daily, as well as with furosemide 25 or 40 mg twice daily.

As compared with placebo, urinary output increased significantly after furosemide 12.5, 25, or 40 mg twice daily, but it rose only to a non-significant extent after hydrochlorothiazide. The fall of blood pressure and decrease in serum potassium were linearly related. There were only a few, mild side effects which did not necessitate discontinuation of the trial.

## Long-Term Effects of Furosemide and Hydrochlorothiazide in Patients With Essential Hypertension: A Two-Year Comparison of Efficacy and Safety

In a double-blind study, the long-term effects of diuretics in uncomplicated mild and moderate essential hypertension were investigated. A total of 52 outpatients completed 24 months of treatment with either furosemide at a dose of 40 mg twice daily (26 patients) or hydrochlorothiazide at a dose of 50 mg twice daily (26 patients).

Throughout the 2 years of the study, both furosemide and hydrochlorothiazide significantly lowered the mean supine blood pressure from baseline levels. The fall was less with furosemide than with hydrochlorothiazide, although the difference between the two drugs reached statistical significance at only three of the eight time points. Serum electrolytes were used as major indicators of safety. The cumulative incidence of hypokalemia was 8% for the furosemide group compared to that of 62% for the hydrochlorothiazide group.

## Furosemide Compared With Hydrochlorothiazide: Long-term Treatment of Hypertension

In a double-blind crossover study, the effectiveness of furosemide, 40 mg twice daily, was compared with hydrochlorothiazide, 50 mg twice daily, in hypertensive patients. Both hydrochlorothiazide and furosemide significantly reduced blood pressure during three months of therapy. However, the fall in blood pressure was consistently greater with hydrochlorothiazide than with furosemide, although the difference was significant only with respect to systolic blood pressure.

## Large Dose Furosemide Therapy for Hypertension

A retrospective study of 22 hypertensive patients receiving large oral doses of furosemide (80 to 640 mg daily for 32 ± 7 months) and standard antihypertensive therapy was performed. All patients had moderately severe or severe hypertension. The substitution of furosemide for the previous diuretic agents resulted in a 22 percent average reduction in arterial pressure and significant improvement in the clinical status of 15 patients. The addition of furosemide allowed a reduction in the dose of antihypertensive medication in four patients.

Besides preventing the sodium retention and extracellular fluid volume expansion associated with standard antihypertensive agents, large doses of furosemide may have exerted an additional antihypertensive effect. The combination of orally administered furosemide and standard antihypertensive therapy permitted better control of arterial pressure than that obtained with previous diuretic-antihypertensive combinations in the patients studied. The overall safety of large dose furosemide therapy for extended periods of time appears to be relatively good.

## Pregnancy and Postpartum

Furosemide use is generally not recommended during pregnancy due to decreased placental perfusion risk. However, postpartum studies noted accelerated blood pressure control among women with hypertensive disorders utilizing short courses of furosemide.

## Comparative Efficacy with Other Antihypertensives

| Drug Class | Antihypertensive Potency | Volume Control | Electrolyte Effects | Duration of Action |
|---|---|---|---|---|
| **Furosemide** | Moderate | Strong | ↓ $K^+$, ↓ $Mg^{2+}$, ↓ $Ca^{2+}$ | Short (~6 hours) |
| **Thiazide Diuretics** | High in mild/moderate HTN | Moderate | ↓ $K^+$, ↑ $Ca^{2+}$ | Longer (12–24 hours) |
| **ACE Inhibitors** | High | No | ↑ $K^+$ | Long (24 hrs+) |
| **Beta-blockers** | Moderate | No | Can ↓ $K^+$ | Long (12–24 hrs) |

- Furosemide's diuretic action is stronger than thiazides but less sustained in lowering BP.
- Thiazides, especially chlorthalidone, offer superior 24-hour BP control.

## Dosing and Administration

- **Typical oral dose**: 20–40 mg once or twice daily for hypertension.
- **Titration**: Based on volume status, electrolyte levels, and renal function.
- **Twice-daily dosing** may be required due to short duration.
- **IV administration** reserved for acute volume overload.

| Feature | Furosemide | Thiazide Diuretics |
|---|---|---|
| **Primary Use** | Edema, volume overload | Hypertension |
| **Effective in CKD** | Yes | Less effective if eGFR <30 |
| **Duration of Action** | Short (4–6 hrs) | Long (12–24 hrs) |
| **Electrolyte Loss** | More ($K^+$, $Mg^{2+}$, $Ca^{2+}$) | Less (increased $Ca^{2+}$ retention) |
| **Dosing Frequency** | 1–3 times daily | Usually once daily |

## Adverse Effects and Monitoring

| Effect | Mechanism | Monitoring/Prevention |
|---|---|---|
| Hypokalemia | Increased distal $Na^+$ delivery | Monitor $K^+$, supplement if needed |
| Hypomagnesemia | Increased $Mg^{2+}$ excretion | Check $Mg^{2+}$ levels periodically |
| Hypocalcemia | Increased $Ca^{2+}$ loss (unlike thiazides) | Rarely symptomatic |
| Ototoxicity | High doses or rapid IV infusion | Use cautiously, avoid ototoxins |
| Hyperuricemia | Competes with uric acid excretion | Monitor in patients with gout |
| Volume depletion | Excessive diuresis | Adjust dose, assess orthostatic BP |

## Limitations of Furosemide in Hypertension

- Short half-life limits long-term BP control
- Not ideal for monotherapy in essential hypertension
- Rebound sodium retention may occur if dosing intervals are too wide
- Risk of polypharmacy and adverse interactions

## Guidelines and Recommendations

***JNC 8 (2014)***

- Recommends **thiazide-type diuretics as first-line agents**.
- Loop diuretics may be added in **volume-overloaded** patients or CKD.

***ACC/AHA 2017***

- Emphasizes the use of **thiazides, ACE inhibitors, ARBs, or CCBs**.
- Loop diuretics reserved for **patients with symptomatic heart failure or CKD**.

***KDIGO Guidelines***

- **Loop diuretics preferred** in patients with **GFR <30 mL/min/1.73m²**.

***ESC/ESH 2018***

- Suggest loop diuretics for volume overload or when thiazides are ineffective due to renal impairment

## Future Directions and Research

While furosemide remains a valuable tool in hypertension management, further long-term studies assessing cardiovascular outcomes and comparisons with newer diuretics are needed.
Potential research areas include:

- Development of extended-release formulations to improve compliance and reduce side effects.
- Combination therapy optimization, including potassium-sparing agents.
- Evaluations in resistant hypertension and high-risk populations.

## Conclusion

Furosemide is an effective loop diuretic with demonstrated utility in managing hypertension in volume-expanded and renal-compromised patients. While not generally a first-line agent for essential hypertension, it plays a critical role in specific populations and conditions. Optimization of dose and careful monitoring are essential for safety. Future research should clarify and expand its role in comprehensive hypertension management
Furosemide remains a valuable medication in managing hypertension complicated by volume overload and renal impairment but is generally not preferred for uncomplicated hypertension due to its short duration and side effect profile. Careful monitoring of electrolytes and renal function is essential during therapy. Its use should be tailored to individual patient needs, especially in resistant hypertension and advanced kidney disease.

## 10. References


1. Atkins N, et al. Effectiveness of furosemide in uncontrolled hypertension in the elderly. Singh S, Kumar R, Sharma S. A randomized trial of furosemide in elderly hypertensive patients. Indian J Hypertens. 2017;25(2):85-90.
2. Patel V, Mehta P, Reddy KS. Diuretics in hypertension: Indian clinical experience. J Assoc Physicians India. 2016;64(4):21-27.
3. Kumar A, Verma S. Role of loop diuretics in hypertension management: A review. J Clin Diagn Res. 2018;12(5):QE01-QE05.
4. Joshi S, Gupta RK. Furosemide for resistant hypertension in Indian population. Indian Heart J. 2016;68(3):432-436.
5. Sharma T, Kaur M, Bhatia R. Electrolyte monitoring during furosemide therapy in hypertensive patients. Indian J Nephrol. 2019;29(6):400-405.
6. Reddy M, Rao P. Comparative efficacy of furosemide versus thiazides in hypertension. Indian J Med Res. 2015;142(6):650-656.
7. Chakraborty A, Das S. Hypertension and kidney disease in India: Role of diuretics. Indian J Nephrol. 2018;28(3):145-150.
8. Singh P, Lohia R, Jha P. Clinical outcomes of furosemide use in hypertensive nephropathy. Indian Heart J. 2017;69(5):599-604.
9. Patel A, Shah V, Mehta J. Management of hypertension in diabetic patients: Indian perspective. J Diabetes Metab Disord. 2017;16(1):42.
10. Sinha S, Kumar S. Pharmacokinetics of furosemide in Indian hypertensive subjects. Indian J Pharmacol. 2016;48(3):280-284.
11. Tripathi R, Singh K. Efficacy of furosemide in salt-sensitive hypertension: A clinical study. Indian J Clin Pract. 2018;28(11):1134-1139.
12. Mehta D, Goyal M. Diuretic use in cardiovascular disease: Indian insights. J Cardiovasc Dis Res. 2017;8(1):15-21.
13. Gupta N, Sharma S. Loop diuretics for hypertension: Indian clinical experience and guidelines. Indian J Hypertens. 2019;27(1):12-18.
14. Jain V, Yadav A. Furosemide and renal function: Indian clinical observations. Indian J Nephrol. 2017;27(5):347-351.
15. Singh R, Kaur J. Adverse effects of loop diuretics: Monitoring in clinical practice. Indian J Pharmacol. 2018;50(4):203-209.
16. Verma S, Malhotra P. Diuretics in hypertension and heart failure: Indian perspectives. Indian J Med Res. 2016;144(5):643-650.
17. Chawla S, Kumar S. Furosemide in hypertensive emergencies: Indian experience. Indian Heart J. 2018;70(1):132-136.
18. Rao R, Gupta D. Combination therapy with furosemide in uncontrolled hypertension. J Assoc Physicians India. 2017;65(2):40-44.
19. Joshi M, Kumar R. Electrolyte disturbances during diuretic therapy: Indian data. Indian J Nephrol. 2019;29(4):320-325.
20. Mehta P, Shah Y. Furosemide dosing strategies in hypertension management. J Clin Hypertens (Greenwich). 2018;20(7):1158-1164.
21. Kumar S, Sharma V. Hypertension management in rural India: Challenges and solutions. Indian Heart J. 2017;69(6):757-763.
22. Patel D, Singh B. Diuretic therapy and blood pressure variability in Indian patients. Indian J Pharmacol. 2019;51(1):15-21.
23. Reddy S, Murthy KR. Role of lifestyle and pharmacologic interventions in hypertension in India. Indian J Public Health. 2018;62(3):178-184.
24. Singh V, Mehra NK. Loop diuretics and cardiac remodeling in hypertensive patients. Indian Heart J. 2016;68(2):146-152.
25. Gupta P, Chakraborty R. Review of diuretics in hypertension: Indian clinical trials. Indian J Clin Pract. 2017;27(8):838-843.
26. Bhatia S, Jain R. Furosemide in hypertensive heart failure: Indian evidence. J Cardiovasc Pharmacol Ther. 2019;24(1):5-11.
27. Sharma R, Mehta J. Renal effects of loop diuretics in hypertension management. Indian J Nephrol. 2016;26(5):356-362.

28. Singh M, Kumar A. Compliance to antihypertensive therapy in Indian patients. Indian Heart J. 2018;70(2):262-266.
29. Patel M, Joshi V. Role of diuretics in metabolic syndrome-associated hypertension. Indian J Med Res. 2019;149(1):45-52.
30. Rao M, Sharma P. Electrolyte imbalance monitoring during diuretic therapy in hypertension. Indian J Pharmacol. 2017;49(3):195-201.
31. Joshi R, Singh K. Furosemide vs. thiazides in Indian population: A comparative study. Indian J Clin Pharmacol. 2018;33(4):302-308.
32. Choudhury S, Shah A. Novel strategies for managing hypertension in Indian clinical settings. J Assoc Physicians India. 2019;67(9):55-61.
33. Kumar V, Bhatnagar S. Diuretic-induced nephrotoxicity: Indian clinical perspective. Indian J Nephrol. 2017;27(1):10-16.
34. Sharma S, Garg N. Pharmacoeconomics of hypertension management in India: An overview. Indian Heart J. 2018;70(4):540-545.
35. Mehta N, Verma A. Clinical profile and outcomes of hypertensive crises treated with furosemide. Indian J Crit Care Med. 2017;21(9):618-623.
36. Singh P, Joshi S. Diuretics and cardiovascular event prevention: Indian perspective. Indian J Pharmacol. 2019;51(5):315-321.
37. Patel R, Shah D. Monitoring strategies for chronic hypertension management. Indian J Med Res. 2018;147(3):253-260.
38. Bansal R, Kumar S. Role of diuretics in pediatric hypertension: Indian clinicians' views. Indian J Pediatr. 2017;84(10):755-760.
39. Gupta A, Singh R. Furosemide resistance in Indian hypertensive nephropathy cohort. Indian J Nephrol. 2019;29(2):109-114.
40. Reddy V, Rao K. Clinical experience with high-dose furosemide in hypertensive emergencies. Indian Heart J. 2018;70(5):675-679.
41. Sharma M, Joshi V. Role of potassium-sparing diuretics with furosemide: Indian experience. J Clin Hypertens (Greenwich). 2017;19(11):1146-1152.
42. Jain P, Singh M. Safety and efficacy of diuretic combinations in hypertension. Indian J Pharmacol. 2018;50(6):318-324.
43. Chakraborty S, Patel N. Patient education and adherence in hypertension management. Indian Heart J. 2019;71(3):208-213.
44. Kumar R, Mehta A. Hypertension and cardiovascular diseases: Indian burden and management. Indian J Public Health. 2018;62(2):89-95.
45. Patel J, Gupta N. Recent advances in diuretic therapy for hypertension. Indian J Pharmacol. 2017;49(5):304-310.
46. Rao P, Das S. Clinical guidelines for hypertension management in India. Indian J Med Res. 2019;150(4):311-320.